Anjali S Advani, William Tse, Hong Li, Xuefei Jia, Paul Elson, Brenda Cooper, Francis Ali-Osman, Jino Park, Arati V Rao, David A Rizzieri, Eunice S Wang, Claudiu V Cotta, Matt Kalaycio, Ronald M Sobecks, Basel Rouphail, Jaroslaw P Maciejewski, Jaime Fensterl, Jennifer S Carew, Bethany Foster, Mary Lynn Rush, Barbara Tripp, Donna Adams, Donna Corrigan, Elizabeth A Griffiths, Mikkael A Sekeres
INTRODUCTION: Adults with acute myeloid leukemia (AML) have a high rate of remission; however, more than 50% relapse. C-kit is expressed in approximately 60% of patients with de novo AML and represents a potential therapeutic target. MATERIALS AND METHODS: Patients with newly diagnosed AML received 12 months of imatinib mesylate as maintenance therapy after the completion of post-remission therapy. The primary objective was to determine whether this approach improved progression-free survival (defined as no relapse and no death) compared with historical controls...
February 2021: Clinical Lymphoma, Myeloma & Leukemia